Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma

NCT01426633 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT01426633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01426633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalating Trial Evaluating the Combination of Gemcitabine and Trabectedin in Patients With Advanced and/or Metastatic Leiomyosarcoma or Liposarcoma
Lead sponsor
Heidelberg University
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2014
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leiomyosarcoma, liposarcoma